Latest immunotherapy news
FDA Approves Subcutaneous Rybrevant Faspro for EGFR-Mutated Non-Small Cell Lung Cancer
posted December 23rd
by modernClinician Editorial Team
by modernClinician Editorial Team
FDA Approves Breyanzi for Relapsed, Refractory Marginal Zone Lymphoma
posted December 15th
by modernClinician Editorial Team
by modernClinician Editorial Team
Timing of Immune Checkpoint Inhibitor Administration Affects Small Cell Lung Cancer Survival
posted December 8th
by modernClinician Editorial Team
by modernClinician Editorial Team
Editor's Recommendations
Thymic Radiation Linked to Worse Outcomes in Patients With NSCLC 
All-Cause Mortality Elevated for Adult Five-Year Survivors of Hodgkin Lymphoma 
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders 
Drug Retention in Spondyloarthritis Varies With Socioeconomic Status Related Articles
Preoperative Chemo + Immunotherapy Combo Shrinks Head, Neck Cancer Tumors 
Cretostimogene Promising for High-Risk, Non-Muscle-Invasive Bladder Cancer 
Omalizumab, Multiallergen OIT Both Viable for Multifood Allergy Treatment 
Enfortumab Vedotin-Pembrolizumab More Effective for MIBC Than Cisplatin-Gemcitabine Monthly Specialist Briefings
Stay Connected
